NYU Langone Health
The proposed study will be a randomized, prospective, non-blinded study of 120 participants with type 1 or type 2 diabetes that are new-to-insulin on hospital discharge. On hospital discharge, participants will be assigned to either the intervention of wearing a continuous glucose monitor (CGM) for 2 weeks or blood glucose monitoring (BGM) for 2 weeks. They will have a 2-week follow up visit, during which insulin doses will be adjusted as needed, and a 3-month follow-up visit, at which point HbA1c will be measured.
Inclusion Criteria: 1. Male or female aged 18-100 years 2. Known history of type 1 or type 2 diabetes 3. Admitted to NYU Langone Hospital - Long Island between December 16, 2024- December 31, 2026 4. New initiation of insulin therapy, including basal insulin regimen, basal-bolus insulin regimen, or mixed insulin regimen at the time of hospital discharge Exclusion Criteria: 1. Prior to admission use of home insulin therapy 2. Current use of systemic corticosteroids 3. Active pregnancy; as pregnancy requires different blood glucose targets, subjects known to be pregnant will be excluded from…
Manufactured by Abbott Diabetes Care Inc. Administered by trained investigator prior to hospital discharge, left in place for 2 weeks duration, then removed.
Self-administered according to investigator instruction.
Arctuva estimate
Verify or correct the compensation shown for this listing.